Abstract In order to capture trends in the contribution of epidemiology to cancer research, we describe an online meta-analysis database resource for cancer clinical and population research and illustrate trends and descriptive detail of cancer meta-analyses from 2008 through 2013. A total of 4,686 cancer meta-analyses met our inclusion criteria. During this 6-year period, a fivefold increase was observed in the yearly number of meta-analyses. Fifty-six percent of meta-analyses concerned observational studies, mostly of cancer risk, more than half of which were genetic studies. The major cancer sites were breast, colorectal, and digestive. This online database for Cancer Genomics and Epidemiology Navigator will be continuously updated to allow investigators to quickly navigate the meta-analyses emerging from cancer epidemiology studies and cancer clinical trials.
Introduction
Cancer clinical and population-based research has undergone rapid growth in the past two decades which has been documented by a vast expansion of scientific literature. Navigating this ''sea of literature'' can be overwhelming, and thus, scientists are increasingly relying on synthesized publications such as meta-analyses to evaluate the body of evidence, help identify scientific gaps, and guide research, policy,and practice. Epidemiology, as a discipline, has provided a scientific foundation for clinical and population studies on a wide spectrum of topics relevant to cancer etiology, prevention, and control. In 2012, the National Cancer Institute (NCI) and the scientific community established eight recommendations to advance the role of epidemiology in medicine and public health [1] . Expanding ''Knowledge Integration (KI)'' was one recommendation for enabling research prioritization through knowledge management and synthesis from multiple disciplines, and facilitating translation of scientific findings into evidencebased recommendations. Knowledge synthesis (including meta-analyses) is a key component of KI and is essential for ''decrypting'' mass quantities of data across various cancer research studies.
Conducting rigorous meta-analyses allows scientists to analyze large datasets and publications and combine different studies using systematic analytic methods. For example, Panagiotou et al. [2] has described the power of meta-analyses in genome-wide association (GWA) studies as having the ability to measure minor genetic outcomes for common traits. In addition, performing meta-analysis of genomic studies significantly increases the statistical power when analyzing ''weaker signals'' [3] . With (AICR) have commissioned coordinated effort on systematic reviews and MAs to assess the state of evidence on food, nutrition, physical activity, body fatness and the prevention of cancer [4] . In clinical medicine, meta-analyses have been utilized to evaluate diagnostic and prognostic markers as well as pharmacologic applications [5] . For example, Ioannidis et al. evaluated cancer risks associated with the use of common medications considering inconsistent published conclusions from the field. The umbrella review of metaanalyses suggested that the credibility of meta-analyses research should be assessed to determine whether a particular clinical question of interest has been addressed appropriately [6] . To our knowledge, there has never been a systematic effort to create a centralized resource of published meta-analyses in cancer clinical and population research. In this report, we introduce a NCI-supported resource, the Cancer Meta-Analyses Database, as a component of the Cancer Genomics and Epidemiology Navigator (CGEN). The URL and information on using this tool can be found via our previous publication [7] and illustrate the trends and overarching landscape of meta-analyses in cancer clinical and population research from 2008 through 2013.
Methods

Search strategy
To ascertain human cancer meta-analytical studies published in the scientific literature during the years 2008 through 2013, we searched PubMed [8] using a text query (see Online Resource 1) and the Human Genome Epidemiology (HuGE) Navigator [9] . The HuGE Navigator, a database of published, population-based epidemiologic studies of human genes extracted from PubMed, offers study-type filtering for meta-analysis. Two reviewers read through abstracts to determine whether the articles met inclusion criteria. For articles without abstracts, full text articles were reviewed.
Inclusion/exclusion criteria
Articles were included if there was a meta-analysis reported on outcomes relevant to the cancer care continuum in humans meeting one or more of the following criteria: (1) risk of disease; (2) diagnostic measure; (3) prognostic measure; (4) treatment of disease, including long-term survival and/or adverse events; and (5) screening for disease. The articles also had to be published in English.
Cancer-related meta-analyses were not included if metaanalyzed data were not derived from human studies, measured short-term treatment outcomes (e.g., length of hospital stay, surgical complications, or treatment-related infection) and systematic reviews without a performed quantitative meta-analysis. Figure 1 presents the search strategy, criteria for selection, and manual coding classification of included articles.
Coding classification
We extracted relevant information (i.e., journal title, year of publication, first author location, and cancer-site MESH terms) from the article abstracts. For the present paper, we identified the following cancer sites: breast, colorectal, digestive, prostate, lung, ovarian, renal, skin, hematologic, endometrial, bladder, other (i.e., bone, head, and neck), and non-specified cancer (i.e., no mention of specific cancer site or combination of many types of cancer). When any one article had multiple cancer-site mesh terms, coding was attributed for each.
We manually coded all relevant meta-analyses for the following information.
Study type
We categorized each meta-analysis according to the study type of the original studies that the meta-analysis utilized: (1) observational, (2) clinical trial, (3) both observational and clinical trial labeled as ''mixed'' or (4) ''not stated'' (for meta-analyses with conclusive information derived or inferred from the abstract). Meta-analyses coded as ''observational'' may include case-control, cross-sectional, and prospective cohort studies with no clinical intervention. Meta-analyses coded as ''clinical trial'' may include randomized and non-randomized control trials. We additionally noted whether meta-analyses of clinical trials restricted their study type to randomized control trials.
Outcome
Each meta-analysis was classified by categories along the cancer care continuum (risk, diagnostic, prognostic, treatment, and/or screening). The ''risk'' coding was assigned to those meta-analyses that assessed any factor associated with cancer risk. ''Diagnostic'' coding included those metaanalyses that evaluated a diagnostic tool or measurement, such as a biomarker, laboratory, and/or radiologic diagnostic methods. ''Prognostic'' meta-analyses were assigned when any tool or measurement provided information regarding survival and/or aggressiveness of disease. Metaanalyses were coded as ''treatment'' when any pharmaceutical, radiologic, and/or surgical/transplant clinical applications were evaluated. ''Screening'' meta-analyses were assigned when the analysis evaluated a cancerscreening or early detection tool.
Exposure
For risk-related meta-analyses, we further assessed whether the type of exposure studied: (1) clinical factor (e.g., pharmaceutical and surgical) and/or (2) modifiable factor (e.g., lifestyle factors, modifiable health conditions, occupational, or environmental exposures). In addition, if the following were noted in the abstract of the article, these were also coded: (1) genomic (e.g., genetic associations, gene expression, epigenetics, or family history), (2) nonmodifiable physiologic measurement, (3) demographic, and/or (4) socioeconomic. Treatment-related meta-analyses were further categorized as ''pharmaceutical,'' ''radiologic,'' and/or ''surgical/transplant.'' The pharmaceutical treatment-related meta-analyses included those studies that measured chemotherapeutic or other pharmaceutical effectiveness, including those measuring adverse side effects of these agents. Radiologic treatment-related metaanalyses included radiotherapy as a treatment method. Surgical/transplant treatment-related meta-analyses were those that measured effectiveness of surgical removal of cancer and/or effectiveness of transplant as a means of treatment. Statistical analysis A nonparametric analysis was performed measuring trends (p trend ) across ordered groups (article count by year). Statistical significance was considered at p \ 0.05. The statistical analysis was performed by Stata/SE 13 software and accessed on 15 June 2015.
Results
Our analytic dataset comprised of 4,686 cancer metaanalyses that met our inclusion criteria from 2008 to 2013. We observed a significant linear trend during this 6-year time period (p trend = 0.030). There was a fivefold increase in the number of published cancer meta-analyses (from n = 285 in 2008 to n = 1,472 in 2013 (Fig. 2) . Table 1 presents the distribution of the study type, cancer care continuum, and cancer site categories by year. With respect to study type, meta-analyses of observational studies comprised 56% (n = 2,647) of the total metaanalyses identified. In the 6-year period, a sixfold increase of meta-analyses of observational studies was observed and they consistently comprised the majority ([50%) of metaanalyses published per year. Twenty percent of the total meta-analyses published were clinical trials (primarily of randomized controlled trials). We were unable to classify the study type of 21% (n = 1,010) of the identified metaanalyses based on review of the abstracts alone.
Risk-associated meta-analyses (n = 2,632, 55%) dominated the published meta-analyses from 2008 to 2013 followed by treatment-related meta-analyses (n = 1,177, 25%) and prognostic-related meta-analyses (n = 519, 11%) ( Table 1 ). There was a marked positive trend (p trend = 0.030) in the publication of risk-related metaanalyses over time with nearly a sixfold increase from 2008 (n = 151) to 2013 (n = 853). Between 2008 and 2013, risk-associated meta-analyses comprised of over half (range from 52 to 56%) per year compared to the total article count for each specific year. A nearly ninefold increase of meta-analyses focused on prognostic outcome was observed from 2008 (n = 29, 10%) to 2013 (n = 224, 15%). Publications of meta-analyses across different categories followed a positive linear trend that were statistically significant (p trend \ 0.05) for all but those metaanalyses that were ''diagnostic'' (p trend = 0.351) and ''screening'' (p trend = 0.093). Figure 3 depicts the selected characteristics of the metaanalyses that were risk-associated. Of the 2,632 metaanalyses that assessed cancer risk: 1,590 (60%) were genomic in nature; 933 (35%) were modifiable risk-factor related; 323 were demographic (12%) measurements; 231 articles (9%) were clinical measurements; and 164 (*6%) were non-modifiable risk factors.
The top four cancer sites assessed by meta-analyses from 2008 to 2013 were breast (n = 656), colorectal (n = 591), digestive (n = 557), and lung (n = 540) ( Table 1) . While meta-analyses focused on breast cancer dominated overall, reports on digestive cancers have increased yearly as shown in 2008 (n = 32), 2009 (n = 48), 2010 (n = 59), 2011 (n = 75), 2012 (n = 143), and 2013 (n = 200). We observed a similar trend for metaanalyses focused on colorectal cancer and lung. All trend tests across categories were statistically significant; p trend = \0.05 (Table 1) .
When we investigated where meta-analyses were published over the 6-year period, the leading journals publishing cancer meta-analyses was PLoS One (n = 391) with the largest contribution submitted in 2012 (n = 111) and 2013 (n = 245) followed by Asian Pacific Journal of Cancer Prevention (n = 195) and Breast Cancer Research and Treatment (n = 188) (Fig. 4) . The Cochrane Database of Systematic Reviews published 93 meta-analyses all together from 2008 to 2013.
In examining the countries from which meta-analyses were performed, we observed that China was the leading country with the highest number of meta-analyses (n = 2,401) within this 6-year time period compared to the USA (n = 579) (Fig. 5) .
When meta-analyses assessing underlying therapeutic factors (n = 1,177) were stratified by cancer sites, lung, colorectal, and breast cancers were the most published meta-analyses that contained a therapeutic component at 16% (n = 187), 14% (n = 165), and 12% (n = 138), respectively. When we examined the types of studies that contained a therapeutic factor, clinical studies were dominant (n = 788; 67%) compared to observational studies (n = 51; 4%) of total published meta-analyses. Of those meta-analyses that examined an underlying genomic factor (n = 1,793), breast cancer was the most common at 17% (n = 304) followed by digestive and colorectal cancer at 12% (n = 220 and n = 216, respectively). Observational studies (n = 1,632; 91%) were the prevailing study type used to assess genomic associations. Clinical meta-analyses incorporated genomics marginally (n = 31; 2%).
Discussion
In the present paper, we described the overall landscape of meta-analyses in the published literature from 2008 to 2013. Our results indicated a substantial upward trend in the quantity of cancer meta-analyses published in this period, particularly for observational studies on risk-related outcomes. Meta-analyses of breast cancer were the leading cancer site reported. It is not surprising that meta-analyses of breast cancer predominated as the proportion of research dollars allocation for breast cancer is consistently high [10] compared to other common cancers such as lung. The results also showed that the top journals publishing metaanalyses were PLoS One, Asian Pacific Journal of Cancer Prevention, and Breast Cancer Research and Treatment.
The rapid growth in meta-analyses was contributed primarily by researchers from China followed by the USA which corroborated a previous study that also showed the explosive productivity rate of meta-analyses in biomedical research, specifically in the field of genetic epidemiology [11] . Meta-analyses increase power. Many individual studies are too small to detect small effects, but when combined, there is a higher probability of detecting an effect. Secondly, meta-analyses improve precision. In addition, meta-analyses settle controversies arising from conflicting studies. Statistical analysis of findings allows the degree of conflict to be evaluated and different results to be measured.
The described meta-analysis database in the present paper is an added feature to the Cancer Genomics and Epidemiology Navigator (CGEN). In 2013, the Epidemiology and Genomics Research Program (EGRP) at the National Cancer Institute (NCI) launched CGEN as a resource for the extramural communities, including EGRP grantees. CGEN is an updated and searchable online tool intended to facilitate cancer epidemiology research [7] . This online database tool provides curated information on EGRP-funded grants, peer-reviewed publications on cancer epidemiology, and genomic evidence-based recommendations. The meta-analysis database, a new addendum to CGEN introduced in 2015, offers a resource for researchers to inform a research direction and identify research gaps.
The meta-analysis database facilitates assessment of the body of evidence on a particular topic related to cancer research that has been meta-analyzed while also having the ability to inquire about active funding by EGRP on a topic. The integrative features of CGEN thus provide users the resource to assess the current view of specific areas of cancer research, appreciate the nuances and gaps in research direction for a particular cancer site and/or exposure of interest, and measure various factors across the basic sciences, clinical, or population studies. Limitations on the utility of the CGEN meta-analysis database include curation based upon publication abstracts only; perhaps, full text review may provide additional data. Furthermore, some meta-analyses may not have been captured through search algorithm, and the database does not contain metaanalyses prior to 2008.
Meta-analyses are one way to synthesize the results of previously conducted research; however, they do have methodological concerns. Not all published meta-analyses are comparable in quality as there is wide heterogeneity in the conduct of the systematic review process as well as the meta-analyses of the published findings. For example, methodological issues include the completeness of the search query, whether the reviewers adhered to rigorous search strategies to address the original scientific question of interest and what protocol was followed to meta-analyzed the published results. High-quality meta-analyses do follow a strict and systematic method of inclusion or exclusion criteria and how to combine data in order to present accurate effect estimates than those attained in individual studies [12] . Therefore, meta-analyses are continually providing the scientific community with an updated and synthesized pool of literature to address research or clinical questions of interest.
It is critical to implement proper practice when conducting meta-analyses. A concise and valuable guide, ''Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)'' has been created to help improve the clearness, accuracy, and comprehensiveness of systematic reviews or meta-analysis protocols of clinical trials [13] . PRISMA 2009 (for protocols) was synthesized containing a checklist of 27 items that are considered essential and necessary elements of a systematic review or meta-analysis. This guide should allow scientist to provide better transparency of their published systematic reviews and meta-analyses. Likewise, Meta-analysis Of Observational Studies in Epidemiology (MOOSE) is a valuable guide that contains checklist items for quality assessment of the meta-analyses for observational studies [14] . Moreover, peer review of meta-analyses for publication should also maintain a rigor to ensure that the meta-analyses are properly conducted and the meta-analysis is methodologically sound.
We attempted to assess the quality of meta-analyses by selecting a random sample of 38 meta-analyses articles in our database. We assessed the quality of reporting of this selected sample against the PRISMA and MOOSE guidelines. We found variability in reporting of RCTs and observational articles (Online Resource 2), suggesting that more diligence may be needed to ensure standards of metaanalyses reporting when peer-reviewed to be published by journals.
The present paper describes a broad overview of the meta-analysis data in CGEN and shows a rapid rise in publications of meta-analyses across several areas. Our hope is that this new feature will provide users with a new resource for their knowledge integrative project or to assess the totality of the field. In-depth analyses using this data can be broad or specific to an area of interest. Furthermore, this continually updated database facilitates and provides researchers with the ability to conduct these analyses needed to continue synthesizing massive data within the field of Cancer Epidemiology.
